Sabby Management, LLC
Sabby Management, LLC is an exempt reporting adviser that reports managing 1 hedge fund on Form ADV. Its private funds, of all types, hold $52.8 million in gross assets. Over a longer period they returned an estimated -50.5% from Q3 2024 to Q2 2026, compared with +43.9% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- —Form ADV Item 5.F
- Gross assets of private funds
- $52.8 millionAll private fund types, Form ADV
- Hedge funds managed
- 12 private funds in total
- Employees
- —Form ADV Item 5.A
- Registration
- Exempt reporting adviserCRD 162659
- Latest Form ADV
- 07/08/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +7.0% | +14.8% |
| Q4 2025 | -53.7% | +2.4% |
| Q3 2025 | +22.8% | +7.8% |
| Q2 2025 | +16.4% | +10.4% |
| Q1 2025 | -18.6% | -4.5% |
| Q4 2024 | -8.8% | +2.1% |
| Q3 2024 | -5.8% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Largest disclosed holdings
- SPDR S&P 500 ETF TR$4.1 million
- Toyo Co LTD$3.5 million
- Farmmi Inc$840,307
- Cervomed Inc$771,528
- Tempest Therapeutics Inc$567,527
- G4289n155$560,519
- Bioaffinity Technologies Inc$296,905
- 168913507$263,214
- Briacell Therapeutics Corp$261,536
- 76135l804$216,899
As of 2026-06-30, from 13F filing by Sabby Management, LLC.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. HedgeMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures